Uro - oncology treatments
搜索文档
Urogen Pharma Q4 Earnings Call Highlights
Yahoo Finance· 2026-03-03 01:15
Since the permanent J-code took effect, management said it has seen acceleration across several launch indicators, including new and repeat prescribers, patient enrollment forms, and new patient starts. Lin said the company was not seeing “material friction points” in reimbursement, logistics, or treatment delivery, and noted growing engagement from community-based urologists, who had been more cautious during the miscellaneous J-code period.Zusduri revenue in 2025 totaled $15.8 million, which Barrett said ...